Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-Risk NMIBC”

88 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 88 results

Large-scale testing (Phase 3)Active Not RecruitingNCT05943106
What this trial is testing

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants

Who this might be right for
Non-Muscle- Invasive Bladder Cancer
AstraZeneca 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07189793
What this trial is testing

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Who this might be right for
Urinary Bladder NeoplasmsCarcinoma, Transitional CellCarcinoma in Situ of Bladder+1 more
First Affiliated Hospital of Wenzhou Medical University 106
Not applicableLooking for participantsNCT06991868
What this trial is testing

Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)

Who this might be right for
NMIBCMIBCUTUC
Peking University First Hospital 300
Not applicableActive Not RecruitingNCT05671900
What this trial is testing

Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer

Who this might be right for
Non-muscle-invasive Bladder Cancer
Clinical Hospital Centre Zagreb 70
Testing effectiveness (Phase 2)Looking for participantsNCT05957757
What this trial is testing

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Who this might be right for
Non-Muscle Invasive Bladder CancerHER2
RenJi Hospital 20
Large-scale testing (Phase 3)Active Not RecruitingNCT03711032
What this trial is testing

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Who this might be right for
High-risk Non-muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC 1,397
Testing effectiveness (Phase 2)Study completedNCT02015104
What this trial is testing

Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG

Who this might be right for
Bladder Cancer
National Cancer Institute (NCI) 32
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06972615
What this trial is testing

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

Who this might be right for
Non Muscle Invasive Bladder Cancer
BLATAM 37
Early research (Phase 1)Study completedNCT05085977
What this trial is testing

Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a)

Who this might be right for
Non-muscle Invasive Bladder Cancer
Protara Therapeutics 12
Testing effectiveness (Phase 2)Active Not RecruitingNCT04706598
What this trial is testing

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Who this might be right for
Urinary Bladder NeoplasmsImmunotherapy
Fudan University 25
Large-scale testing (Phase 3)Looking for participantsNCT06696794
What this trial is testing

Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients

Who this might be right for
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Shaogang Wang 180
Large-scale testing (Phase 3)Active Not RecruitingNCT05538663
What this trial is testing

Intravesical BCG vs GEMDOCE in NMIBC

Who this might be right for
Non-muscle-invasive Bladder Cancer
ECOG-ACRIN Cancer Research Group 870
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06588179
What this trial is testing

SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt

Who this might be right for
NMIBC
Fudan University 58
Large-scale testing (Phase 3)Looking for participantsNCT05037279
What this trial is testing

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients with Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC)

Who this might be right for
Bladder CancerBladder Cancer RecurrentNeoplasm Recurrence+3 more
Verity Pharmaceuticals Inc. 540
Large-scale testing (Phase 3)Active Not RecruitingNCT04452591
What this trial is testing

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Who this might be right for
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
CG Oncology, Inc. 190
Not applicableEnded earlyNCT04412070
What this trial is testing

Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC Patients

Who this might be right for
Bladder Cancer
Hopital Foch 20
Large-scale testing (Phase 3)WithdrawnNCT01284205
What this trial is testing

First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC

Who this might be right for
Bladder Cancer
Bioniche Life Sciences Inc.
Testing effectiveness (Phase 2)Ended earlyNCT03519256
What this trial is testing

Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Who this might be right for
Urinary Bladder Neoplasms
Bristol-Myers Squibb 142
Testing effectiveness (Phase 2)Active Not RecruitingNCT03504163
What this trial is testing

Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]

Who this might be right for
Bladder Cancer
Memorial Sloan Kettering Cancer Center 45
Large-scale testing (Phase 3)Active Not RecruitingNCT06211764
What this trial is testing

TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

Who this might be right for
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC 272
Load More Results